Chimerix INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
CMRX
Chimerix INC10-K/A: Chimerix Amends Annual Report Following $935 Million Acquisition Agreement with Jazz Pharmaceuticals
Chimerix files an amendment to its 2024 annual report to include Part III information due to the pending acquisition by Jazz Pharmaceuticals for $935 million.
CMRX
Chimerix INCChimerix has entered into a merger agreement with Jazz Pharmaceuticals for approximately $935 million and filed its 10-K report detailing its financial results for the year ended December 31, 2024, along with updates on its drug development programs.
CMRX
Chimerix INCChimerix, a biopharmaceutical company, released its 2023 financial results and provided updates on its clinical development programs, including the ongoing Phase 3 ACTION study for ONC201.